Combined Immune Deficiency (CID) Market

Introduction

A formation of group of inherited immune disorders in which lymphocyte functions are impaired and lymphocyte numbers may be diminished is called Combined immune deficiencies (CIDs).These disorders affect the T-cells which disturbs their ability to provide assistance in production of antibodies and therefore causing decreased immunoglobulins. Combined immune deficiency (CID) as a result of defects caused by the gene mutations in the immune system.

The Covid-19 has a positive impact on the Combined Immune Deficiency (CID) Market. The patients with immune deficiency disorders are more prone to developing infectious diseases. The Covid-19 virus has a significant impact on the immune system leading to rising no. of patients with immune deficiency disorders seek consistent treatment.

Combined Immune Deficiency (CID) Market: Drivers and Restraints

The prevalence of immunodeficiency diseases is on a rise across the globe. According to a study conducted by American academy of pediatrics, the calculated prevalence of diagnosed primary immune deficiency was 1 in 2000 children and 1 in 600 households. This rise in research and development activities that focus on identifying the gene that could cause combined immune deficiency are expected to accelerate new drug development and gene-sequencing. This is expected to drive the growth of the Combined Immune Deficiency (CID) Market.

However, the lack of awareness amongst end users and the non-availability of diagnostic facilities in underdeveloped and developing countries with resource constraints is likely to leave this disease under recognized. This will in-turn restrict the growth of the Combined Immune Deficiency (CID) market. Additionally, lack of adequate reimbursement and high cost of the therapies required for treatment may also restrain the growth of the Combined Immune Deficiency (CID) market.

Combined Immune Deficiency (CID) Market: Overview

Combined Immune Deficiency (CID) Market is expected to witness substantial growth as a result of increasing incidence of Combined Immune Deficiency globally during the forecast period.

Based on therapy type, the gene therapy is expected to dominate the Combined Immune Deficiency (CID) Market during the forecast period. The promising results of recent clinical trials is expected to make gene therapy prominent in the treatment of combined immune deficiency

In the end user segment, the hospitals are expected to hold the largest share in the Combined Immune Deficiency (CID) Market. However, the rigorous research and development activities and the increased focus of the government to encounter immune deficiency disorders is expected to lead considerable growth in the research and development segment.

Combined Immune Deficiency (CID) Market: Regional-Wise Outlook

Geographically, the Combined Immune Deficiency (CID) Market is segmented into seven regions viz. East Asia, South Asia, Latin America, Europe, Oceania, North America and Middle East & Africa. North America is expected to hold the largest market share, this is due to rise in prevalence of immune deficiency disorders in this region.

According to a study conducted by immune deficiency foundation, suggested that the prevalence of diagnosed primary immune deficiency in U.S. is approximately 1 in 1,200 persons. Moreover, the rise is healthcare expenditure and the presence of well-established healthcare system and key players are driving the growth of the Combined Immune Deficiency (CID) market in this region.

East Asia and South Asia is anticipated to experience considerable growth in the Combined Immune Deficiency (CID) market during the forecast period. The rising efforts by the medical system by increasing R&D activities to advance the healthcare system is leading to considerable growth of Combined Immune Deficiency (CID) Market in this region. For instance, the Indian council of medical research funded 2 research centers for advanced research in primary immune deficiency. These centers are actively involved since 2010 in taking care of the patients with primary immuno deficiency.

Combined Immune Deficiency (CID) Market: Key players

Some of the players identified in the Combined Immune Deficiency (CID) Market include:

• LFB SA
• Shire plc
• Kedrion Biopharma Inc
• CSL Behring
• Octapharma
• China Biologic Products Holdings, Inc
• Sanquin,
• Grifols, S.A
• Biotest AG,
• Baxter International Inc.

The report is a compilation of first-hand information, qualitative and quantitative assessment by industry analysts, inputs from industry experts and industry participants across the value chain. The report provides in-depth analysis of parent market trends, macro-economic indicators and governing factors along with market attractiveness as per segments. The report also maps the qualitative impact of various market factors on market segments and geographies.

• Market Segments
• Market Dynamics
• Market Size
• Supply & Demand
• Current Trends/Issues/Challenges
• Competition & Companies involved
• Technology Matrix
• Value Chain

Regional analysis of the Combined Immune Deficiency  market report includes

• North America
• Latin America
• Europe
• South Asia
• East Asia
• Oceania
• Middle East and Africa

Combined Immune Deficiency  marketReport Highlights:

• Overview of Global Healthcare Market
• Evolution of the technology
• Changing market dynamics in the industry
• In-depth market segmentation
• Historical, current and projected market size in terms of value
• Recent industry trends and developments
• Competitive landscape
• Strategies of key players and products offered
• Potential and niche segments, geographical regions exhibiting promising growth
• A neutral perspective on market performance
• Must-have information for market players to sustain and enhance their market footprint.

Combined Immune Deficiency (CID) Market: Segmentation

Tentatively, the global Combined Immune Deficiency (CID) Market has been segmented on the basis of disease type, therapy type and end user.

Based on disease type, the global Combined Immune Deficiency (CID) Market is segmented as:

• Antibody Deficiency
• Cellular Immunodeficiency
• Innate Immune Disorders

Based on therapy type, the global Combined Immune Deficiency (CID) Market is segmented as:

• Immunoglobulin Replacement Therapy
• Bone marrow transplant
• Stem cell transplant
• Lung transplant
• Gene therapy
• Others

Based on end user, the global Combined Immune Deficiency (CID) Market is segmented as:

• Hospitals
• Ambulatory surgical care
• Research and development institutes